Artiva Biotherapeutics, Inc.
ARTVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Artiva Biotherapeutics, Inc. focuses on Biotechnology services and products. Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. With a market capitalization of $474.2M, it sits in small-cap territory. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Market Cap
$474.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-3.47
EPS (TTM)
$-3.83
EPS (Fwd)
$-2.81
ROE
-67.9%
ROA
-38.7%
Cash
$86.8M
Total Debt
$10.3M
Free CF
-$49.4M
52W Change
308.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $86.8M in cash comfortably exceeding the $10.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$49.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -67.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $4.9M (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, ARTV has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Artiva Biotherapeutics, Inc.'s trajectory.